Abstract:Abstract Lung cancer is the leading cause of cancer related deaths worldwide, with the most prevalent subtype being non-small cell lung cancer (NSCLC). As only a subset of patients exhibits durable clinical responses to current treatments, including targeted therapy and immunotherapy, new treatment options are needed. Integrins (ITGs) are a diverse class of heterodimeric, transmembrane receptors that bind extracellularly to the extracellular matrix (ECM) and intracellularly to the cytoskeleton to integrate signals bi-directionally between the extracellular environment and cell interior. One of 18 α subunits is paired with one of 6 β subunits to create the 24 known αβ ITGs in mammals. ITGs are expressed at low levels in normal tissue and can be upregulated in cancer cells in response to stress signals in the tumor microenvironment (TME). Altered expression of ITGs is associated with enhanced cell proliferation, metastasis, and immune evasion. Targeting of the diverse ITG family members by inhibitors not specific to individual isoforms has obscured understanding of potentially distinct functions of each heterodimer. Through data mining of a genome wide CRISPR screening publicly available at the DepMap portal, we have identified a novel cancer dependency to ITG αvβ5 in approximately 40% of NSCLC cell lines. Using small molecule ITG αv inhibitors, we have mirrored sensitivity of NSCLC cell lines to their ITG αvβ5 CRISPR scores, suggesting that these inhibitors function specifically through ITG αvβ5 in cell lines. RNA sequencing analysis following αvβ5 inhibition in human NSCLC cell lines revealed downregulation of YAP and E2F1 target genes with alterations in gene ontologies associated with cell cycling and cell death in sensitive, but not resistant, lines. This is consistent with the known function of YAP driving gene transcription promoting cell proliferation and survival, and of E2F1 being implicated in regulating the proliferation and self-renewal of cancer stem cell (CSC). Additional changes to immune processes, specifically perturbations to interferon (IFN) pathways, were identified in response to ITG αvβ5 inhibition, suggesting that ITG αvβ5 may play a role in host anti-tumor immune responses. Pharmacological inhibition of ITG αvβ5 also led to a reduction of tumor growth in NSCLC murine models accompanied with increased CD8 T cell activation. These findings support ITG αvβ5 as a unique target of cancer dependency in NSCLC whose inhibition promotes anti-tumor responses through both tumor intrinsic and host immune regulatory mechanisms. Citation Format: Bitta P. Kahangi, William P. Crosson, Ji-Ann Lee, Camelia Dumitras, Tianhao Zhang, Ramin Salehi-Rad, Linh M. Tran, Michael Palazzolo, Dylan Conklin, Steven M. Dubinett, Bin Liu. Evaluation of integrin alpha v beta 5 as a novel target for non-small cell lung cancer via tumor intrinsic and host immune regulation [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2024; Part 1 (Regular Abstracts); 2024 Apr 5-10; San Diego, CA. Philadelphia (PA): AACR; Cancer Res 2024;84(6_Suppl):Abstract nr 4266.

Correlation of Cell Proliferation Inhibition and Apoptosis Induction with Expression of Human Beta 5 Integrin on Hematopoietic Cells

[Correlation of Cell Apoptosis Induction with Expression of Human Beta5 Integrin on Hematopoietic Cells].

Corelation of cell proliferation in hibition and apoptosis induction with expression of human β5 integrin on hematopoietic cells

Enhancement of Endothelial Cell Migration and In Vitro Tube Formation by TAP20, A Novel beta5 Integrin-Modulating, PKCtheta-Dependent Protein

Over Expression of Integrin Α 5 Β 1 in Human Hepatocellular Carcinoma Cell Line Suppresses Cell Proliferation in Vitro and Tumorigenicity in Nude Mice

Effects of integrin αvβ6 on endo-exocytotic cycle of integrin αvβ5 in colon cancer cells

Integrin αvβ5 as a biomarker for the assessment of non-small cell lung cancer metastasis and overall survival.

All-trans-retinoic Acid Increased the Expression of Integrin Alpha5beta1 and Induced "anoikis" in SMMC-7721 Hepatocarcinoma Cell.

Preclinical evaluation of an anti-alpha5beta1 integrin antibody as a novel anti-angiogenic agent

TGF-β1 Modulated the Expression of Α5β1 Integrin and Integrin-Mediated Signaling in Human Hepatocarcinoma Cells

Expression of the Integrin Α 5 Subunit and Its Mediated Cell Adhesion in Hepatocellular Carcinoma

S-Phase Delay in Human Hepatocellular Carcinoma Cells Induced by Overexpression of Integrin Beta 1

Abstract 4266: Evaluation of integrin alpha v beta 5 as a novel target for non-small cell lung cancer via tumor intrinsic and host immune regulation

The Roles of Integrin α5β1 in Human Cancer

Integrin Beta 5 Is a Prognostic Biomarker and Potential Therapeutic Target in Glioblastoma

Integrin α5β1 and p53 convergent pathways in the control of anti-apoptotic proteins PEA-15 and survivin in high-grade glioma

Insulin-like growth factor receptor cooperates with integrin alpha v beta 5 to promote tumor cell dissemination in vivo.

[Correlation Between Integrin Subunits Alpha5 and Beta1 Expressions in Prostate Cancer and Its Clinical Implication].

[Beta1 Integrin Dysfunction in Adult Chronic Myeloid Leukemia Bone Marrow Cells]

[Restoring Beta1 Integrin Activation Function in K562 Cells Transfected with Antisense VEGF121 Cdna].

Increased Integrin Α5β1 Heterodimer Formation and Reduced C‐jun Expression Are Involved in Integrin Β1 Overexpression‐mediated Cell Growth Arrest